Loading...
Explore Sai Parenteral's IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company established in 2001. The company engages in the research, development, and manufacturing of pharmaceutical products.
Core Business: Sai Parenteral's operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
Main Products/Services: The company offers a broad product portfolio across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Their offerings are available in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Industry Focus: Pharmaceutical formulations.
Key Highlights:
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 24 Mar - 27 Mar 2026 |
| IPO Price Band | ₹372 - ₹392 per share |
| Fresh Issue | 285.00 Cr |
| Offer For Sale | 123.79 Cr |
| Total IPO Size | 408.79 Cr |
| Face Value | 5 |
| Listing On | BSE, NSE |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 24 Mar 2026 |
| IPO Closing Date | 27 Mar 2026 |
| Basis Of Allotment | 30 Mar 2026 |
| Refunds | 01 Apr 2026 |
| Demat Transfer | 01 Apr 2026 |
| IPO Listing Date | 02 Apr 2026 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | 30 Sep 2025 |
|---|---|---|---|---|
| Assets | 133.96 | 268.10 | 272.39 | 376.24 |
| Total Income | 97.03 | 155.18 | 163.74 | 89.43 |
| Profit After Tax | 4.38 | 8.42 | 14.43 | 7.76 |
| EBITDA | 17.64 | 31.70 | 39.44 | 16.24 |
| NET Worth | 31.49 | 76.40 | 95.78 | 209.37 |
| Reserves and Surplus | 24.34 | 61.30 | 80.36 | 188.84 |
| Total Borrowing | 68.55 | 118.79 | 93.95 | 76.07 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Sai Parenteral's Limited | 72.19 | 5.43 | 15.09% | 35.98 |
| Gland Pharma Limited | 44.71 | 42.4 | 7.63% | 555.41 |
| Senores Pharmaceuticals Limited | 64.3 | 16.12 | 7.18% | 176.37 |
| Innova Captab Limited | 32.45 | 22.41 | 13.37% | 167.66 |
| Sai Life Sciences Limited | 107.7 | 8.61 | 7.99% | 102.12 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not more than 50% of the Net Offer |
| Non-Institutional Investor (NII/HNI) | Not less than 15% of the Net Offer |
| Retail Individual Investor (RII) | Not less than 35% of the Net Offer |
As the issue has not yet opened, subscription data is unavailable. However, you can view subscriptions for other ongoing issues here.
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, –500032
Website:https://www.saiparenterals.com/
Phone:+91 79979 91301
Email:cs@saiparenterals.com